Tuberculosis Clinical Trial
Official title:
A Cluster Randomised Trial to Assess the Impact of an Enhanced Case Finding Strategy on Tuberculosis Notification in The Gambia
This is a cluster Tuberculosis (TB) randomized trial in which enhanced case finding (ECF)
strategy will be compared to passive TB case reporting in The Gambia. And that the impact of
ECF on community and household transmission of TB will also be assessed.
The hypothesis is a cluster randomized trial of an enhanced case finding (ECF) strategy will
increase TB case notifications in The Gambia and reduce TB burden in the study area in a cost
effective manner. The impact of ECF on community and household transmission of TB will also
be assessed. The investigators hope this trial will contribute to this evidence base. The
timing alongside a nationwide TB prevalence survey is particularly of benefit as that would
provide a baseline for disease burden against which the investigators may be able to compare
case notification or case detection in selected clusters
TB is a chronic, transmissible disease, albeit with effective and curative combination
therapeutic regimens available. However insufficient case detection, delayed diagnosis of TB
, which prolong the duration of potential transmission, and co prevalent HIV/AIDS are the
major factors responsible for increasing TB incidence. The DOTs strategy, which relies on a
process of passive TB case finding, has helped to control TB in many parts of the world.
Currently, the World Health Organisation's Stop TB DOTS policy is being questioned as
countries that have reached and maintained targets of 70% case detection and 85% cure rates
are unable to demonstrate a decline in number of cases notified.
Studies in Southern Africa suggest that if the investigators want to prevent TB in
HIV-infected and uninfected people a major focus should be on decreasing transmission from
people who are HIV-negative that may transmit TB for a long time on account of delayed
diagnosis 5, 6. Data from studies in Ethiopia, Peru, Brazil, and Zimbabwe show different
strategies of intensified or active case finding (ICF or ACF) yield significantly more TB
cases than the standard of care-passive case finding.7-10 In the Zimbabwe study, point
prevalence of TB declined significantly over 2 time points and was attributed to the ICF
intervention. Since effective treatment for TB renders patients non-infectious within 2-4
weeks, it is likely that earlier diagnosis and initiation of treatment will ultimately reduce
the incidence of TB by interrupting TB transmission. However the quantitative effect of
enhanced case finding (ECF) on TB case notification rates, TB transmission, prevalence and
incidence remains largely unproven.
Although there is now data from Zimbabwe regarding the impact of untargeted active case
finding strategies, it is unclear how each case finding strategy compares to the standard
passive case finding and the investigators are currently unable to address the cost
effectiveness or otherwise of active case finding strategies in high TB burden settings with
low HIV prevalence which is the scenario in most West African countries including The Gambia.
Consequently, there is insufficient data to support a policy change and an urgent need for
evidence to drive the necessary review of policy.
The hypothesis is a cluster randomized trial of an enhanced case finding (ECF) strategy will
increase TB case notifications in The Gambia and reduce TB burden in the study area in a cost
effective manner. The impact of ECF on community and household transmission of TB will also
be assessed. The investigators hope this trial will contribute to this evidence base. The
timing alongside a nationwide TB prevalence survey is particularly of benefit as that would
provide a baseline for disease burden against which the investigators may be able to compare
case notification or case detection in selected clusters.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05738681 -
Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial
|
Phase 2/Phase 3 | |
Recruiting |
NCT05526885 -
Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa
|
N/A | |
Completed |
NCT04369326 -
Community Initiated Preventive Therapy for TB
|
N/A | |
Recruiting |
NCT04568967 -
TB-CAPT EXULTANT - HIV
|
N/A | |
Completed |
NCT02337270 -
Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol
|
Phase 1 | |
Not yet recruiting |
NCT06253715 -
Shortened Regimen for Drug-susceptible TB in Children
|
Phase 3 | |
Recruiting |
NCT04271397 -
Immunological Biomarkers in Tuberculosis Management
|
N/A | |
Withdrawn |
NCT03639038 -
Tuberculosis Diagnosis by Flow Cytometry
|
||
Completed |
NCT03199313 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid
|
Phase 1 | |
Recruiting |
NCT04975178 -
Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
|
Phase 3 | |
Completed |
NCT04463680 -
Rifampin and the Contraceptive Implant
|
Phase 4 | |
Completed |
NCT03973970 -
Assessing the Ability of the T-SPOT®.TB Test (IQ)
|
||
Recruiting |
NCT04230395 -
Alcohol Reduction Among People With TB and HIV in India
|
N/A | |
Completed |
NCT04874948 -
Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
|
Phase 1 | |
Active, not recruiting |
NCT02906007 -
Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05917210 -
Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda
|
N/A | |
Not yet recruiting |
NCT05845112 -
Start Taking Action For TB Diagnosis
|
||
Not yet recruiting |
NCT06017843 -
Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding
|
N/A | |
Active, not recruiting |
NCT02715271 -
Study of TB Lesions Obtained in Therapeutical Surgery
|
||
Completed |
NCT02781909 -
Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis
|
Phase 2 |